Roche Holding : Q3 sales slightly ahead of expectations - full-year guidance confirmed
>Good performance in pharma - The group’s Q3 sales came in 1.7% above the consensus, showing growth of 9% at CER (6% CHF). The pharma division showed growth of 10% at CER (6.6% CHF) coming in 2.6% ahead of the css, given that 45% of the beat stemmed from the performance of Actemra/RoActemra (3.9%, 20% vs css), a product that is gradually coping with competition from biosimilars. At the level of core products, growth is driven mainly by Vabysmo (56%, 4% vs css), Hemlib...Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.